Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -9.82 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 499.13 | 1434.82 | 533.59 | 202.17 | 289.06 | 138.24 | 66.24 | 113.20 | 63.79 | 68.47 | 157.17 | 287.58 | 40.90 | 10.36 | 31.54 | 30.79 | 30.09 | 75.11 | 232.29 | 126.74 | 138.46 |
| — | +937.9% | +705.5% | +78.6% | +353.2% | +101.9% | -57.9% | -60.6% | +55.9% | +560.7% | +398.3% | +833.9% | +35.9% | -86.2% | -86.4% | -75.7% | -78.3% | — | — | — | — | |
| P/B Ratio | 5.96 | 7.42 | 2.67 | 2.77 | 2.08 | 1.89 | 1.57 | 1.68 | 2.16 | 1.57 | 2.35 | 2.21 | 0.62 | 0.65 | 0.63 | 0.70 | 0.97 | 0.95 | 2.23 | 2.01 | 2.20 |
| — | +292.1% | +69.8% | +65.1% | -3.6% | +20.4% | -33.2% | -23.8% | +247.8% | +142.4% | +273.0% | +215.8% | -36.3% | -31.9% | -71.8% | -65.2% | -55.7% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -319.4% | 100.0% | -1168.8% | -335.1% | 100.0% | -3349.9% | -1288.0% | -2452.9% | -97.2% | -1101.7% | -1262.6% | -3382.0% | -1382.4% | -259.7% | -176.1% | -130.3% | -43.7% | -213.5% | -1740.9% | -90.0% | 100.0% |
| — | +103.0% | +9.2% | +86.3% | +202.8% | -204.1% | -2.0% | +27.5% | +93.0% | -324.2% | -616.9% | -2495.2% | -3064.1% | -21.7% | +89.9% | -44.8% | -143.7% | +84.9% | -1840.9% | -31.4% | 0.0% | |
| Operating Margin | -4454.2% | -10741.5% | -14347.0% | -5560.3% | -7977.2% | -5293.9% | -2351.9% | -4477.3% | -1698.7% | -2104.0% | -2616.7% | -7319.2% | -3132.1% | -1276.7% | -1929.5% | -1354.7% | -1180.5% | -2882.9% | -3516.8% | -1808.3% | -1373.7% |
| — | -102.9% | -510.0% | -24.2% | -369.6% | -151.6% | +10.1% | +38.8% | +45.8% | -64.8% | -35.6% | -440.3% | -165.3% | +55.7% | +45.1% | +25.1% | +14.1% | -25.7% | -235.3% | -964.7% | -215.6% | |
| Net Margin | -4113.7% | -10443.4% | -13767.0% | -4548.0% | -7594.2% | -5155.0% | -2234.6% | -4358.3% | -1610.7% | -1948.8% | -2447.1% | -6966.0% | -2956.2% | -1237.7% | -1840.4% | -1250.5% | -1150.7% | -2862.3% | -3601.2% | -1733.2% | -1535.7% |
| — | -102.6% | -516.1% | -4.4% | -371.5% | -164.5% | +8.7% | +37.4% | +45.5% | -57.5% | -33.0% | -457.0% | -156.9% | +56.8% | +48.9% | +27.8% | +25.1% | +49.4% | -249.2% | -857.3% | -230.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -62.5% | -15.9% | -16.4% | -14.8% | -15.0% | -16.4% | -13.9% | -15.2% | -13.0% | -10.7% | -10.6% | -12.6% | -10.7% | -17.8% | -8.8% | -6.9% | -9.0% | -8.7% | -8.3% | -6.7% | -11.1% |
| — | +3.3% | -17.5% | +2.9% | -15.5% | -53.2% | -32.1% | -20.5% | -21.3% | +39.6% | -19.4% | -84.1% | -19.3% | -103.3% | -5.9% | -2.8% | +19.5% | +89.4% | +50.5% | +9.5% | — | |
| ROA | -53.6% | -14.3% | -14.4% | -12.8% | -12.6% | -13.8% | -11.8% | -12.9% | -11.2% | -9.3% | -8.9% | -10.4% | -9.0% | -15.2% | -7.6% | -5.9% | -7.7% | -7.5% | -7.2% | -5.8% | -6.7% |
| — | -3.5% | -21.7% | +0.8% | -13.0% | -48.1% | -32.3% | -24.4% | -24.5% | +38.4% | -17.9% | -76.0% | -16.1% | -101.3% | -5.5% | -2.5% | -15.4% | +56.1% | -2.0% | -3.1% | — | |
| ROIC | -58.0% | -16.5% | -13.5% | -14.2% | -12.9% | -15.5% | -13.5% | -13.8% | -11.8% | -10.3% | -11.2% | -14.0% | -11.0% | -14.7% | -7.3% | -7.0% | -12.0% | -16.0% | -16.2% | -14.9% | -13.3% |
| — | -6.6% | -0.3% | -2.7% | -9.5% | -50.0% | -20.5% | +1.6% | -7.5% | +29.8% | -52.6% | -99.5% | +8.4% | +8.0% | +54.8% | +52.8% | +9.7% | +13.4% | +62.4% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.01 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.06 | 0.06 | 0.06 | 0.06 | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.09 | 0.09 | 0.05 | 0.05 | 0.06 |
| — | -65.0% | -42.8% | -50.4% | -50.3% | -29.0% | -24.4% | -37.4% | -34.1% | -33.4% | -29.1% | +7.6% | +0.7% | +3.1% | +56.3% | +53.2% | +60.4% | -98.1% | -97.7% | -74.7% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.57 | 10.63 | 6.59 | 6.57 | 5.89 | 4.39 | 5.72 | 4.67 | 5.63 | 6.49 | 7.19 | 4.08 | 4.82 | 5.81 | 6.08 | 6.17 | 6.71 | 7.19 | 6.11 | 8.07 | 9.94 |
| — | +142.3% | +15.2% | +40.7% | +4.7% | -32.4% | -20.5% | +14.5% | +16.8% | +11.7% | +18.3% | -33.9% | -28.2% | -19.2% | -0.6% | -23.5% | -32.5% | +90.4% | -42.7% | +11.2% | — | |
| Quick Ratio | 6.57 | 10.63 | 6.59 | 6.57 | 5.89 | 4.39 | 5.72 | 4.67 | 5.63 | 6.49 | 7.19 | 4.08 | 4.24 | 5.81 | 6.08 | 5.68 | 6.71 | 7.19 | 6.11 | 7.75 | 9.94 |
| — | +142.3% | +15.2% | +40.7% | +4.7% | -32.4% | -20.5% | +14.5% | +32.6% | +11.7% | +18.3% | -28.1% | -36.7% | -19.2% | -0.6% | -26.8% | -32.5% | +90.4% | -42.7% | +6.9% | — | |
| Interest Coverage | -549.78 | -16584.00 | -1644.39 | -1023.97 | -634.60 | -542.54 | -332.54 | -260.31 | -209.47 | -164.00 | -123.79 | -118.82 | -101.76 | -84.58 | -71.74 | -68.59 | -97.82 | -136.20 | -143.86 | -130.34 | -31.99 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABSI stock.
Absci Corporation's current P/E is -9.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Absci Corporation's current operating margin is -4454.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Absci Corporation's business trajectory between earnings reports.